PMID- 30938842
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20210109
IS  - 1098-108X (Electronic)
IS  - 0276-3478 (Print)
IS  - 0276-3478 (Linking)
VI  - 52
IP  - 7
DP  - 2019 Jul
TI  - A double-blind, placebo-controlled study of vortioxetine in the treatment of 
      binge-eating disorder.
PG  - 786-794
LID - 10.1002/eat.23078 [doi]
AB  - BACKGROUND: Binge-eating disorder (BED) is associated with impaired quality of 
      life and has a number of untoward public health associations. There are few 
      established pharmacological treatments for BED, and available options are not 
      suitable for all individuals. Vortioxetine is a recently developed 
      pharmacological agent with effects on the serotonergic but also other 
      neurochemical systems, which has yet to be evaluated in this context. METHOD: 
      Eighty adults with BED were recruited for a double-blind, placebo-controlled 
      study. Participants received 12-week treatment with vortioxetine (10 mg/day for 
      1 week, then increasing to 20 mg/day) or placebo in a parallel design. The 
      primary efficacy outcome measures were binge-eating frequency and weight. Safety 
      data were collected. Effects of active versus placebo treatment were 
      characterized using linear repeated measures models. RESULTS: Both vortioxetine 
      and placebo treatment were associated with significant reductions in binge-eating 
      frequency. Vortioxetine did not differentiate significantly from placebo on any 
      efficacy measure. Frequency of adverse events did not differ between groups. 
      DISCUSSION: Vortioxetine was not more effective than placebo in the treatment of 
      BED. The ability to detect pharmacological treatment benefit may have been 
      hindered by the relatively high placebo response and drop out. Future work should 
      seek to better understand and predict placebo response in BED, with a view to 
      more targeted treatment interventions and, potentially, sample enrichment.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Grant, Jon E
AU  - Grant JE
AUID- ORCID: 0000-0001-7784-7021
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 
      Chicago, Illinois.
FAU - Valle, Stephanie
AU  - Valle S
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 
      Chicago, Illinois.
FAU - Cavic, Elizabeth
AU  - Cavic E
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 
      Chicago, Illinois.
FAU - Redden, Sarah A
AU  - Redden SA
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 
      Chicago, Illinois.
FAU - Chamberlain, Samuel R
AU  - Chamberlain SR
AUID- ORCID: 0000-0001-7014-8121
AD  - Department of Psychiatry, University of Cambridge; Cambridge and Peterborough NHS 
      Foundation Trust (CPFT), UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 110049/WT_/Wellcome Trust/United Kingdom
GR  - 110,049/Z/15/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190402
PL  - United States
TA  - Int J Eat Disord
JT  - The International journal of eating disorders
JID - 8111226
RN  - 0 (Antidepressive Agents)
RN  - 3O2K1S3WQV (Vortioxetine)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Binge-Eating Disorder/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Quality of Life/*psychology
MH  - Treatment Outcome
MH  - Vortioxetine/pharmacology/*therapeutic use
PMC - PMC7102903
MID - EMS86095
OTO - NOTNLM
OT  - antidepressant
OT  - binge eating
OT  - obesity
OT  - pharmacology
OT  - treatment
COIS- Conflicts of Interest and Disclosures This study was funded by an 
      investigator-initiated research grant from Takeda Pharmaceuticals to Dr. Grant. 
      Dr. Grant receives yearly compensation from Springer Publishing for acting as 
      Editor-in-Chief of the Journal of Gambling Studies and has received royalties 
      from Oxford University Press, American Psychiatric Publishing, Inc., Norton 
      Press, and McGraw Hill. Dr. Chamberlain consults for Cambridge Cognition, Shire 
      and Promentis. Ms. Redden report no financial relationships with commercial 
      interests. Dr. Chamberlain's involvement in this study was supported by a 
      Wellcome Trust Clinical Fellowship (110049/Z/15/Z).
EDAT- 2019/04/03 06:00
MHDA- 2019/12/18 06:00
PMCR- 2020/03/28
CRDT- 2019/04/03 06:00
PHST- 2019/01/21 00:00 [received]
PHST- 2019/03/13 00:00 [revised]
PHST- 2019/03/13 00:00 [accepted]
PHST- 2019/04/03 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/04/03 06:00 [entrez]
PHST- 2020/03/28 00:00 [pmc-release]
AID - 10.1002/eat.23078 [doi]
PST - ppublish
SO  - Int J Eat Disord. 2019 Jul;52(7):786-794. doi: 10.1002/eat.23078. Epub 2019 Apr 
      2.